Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III trial of tosedostat in elderly patients with high risk myelodysplastic syndromes or secondary acute myeloid leukaemia who have failed to respond adequately to hypomethylating agents.

Next Previous
Search
Trial Profile

Phase III trial of tosedostat in elderly patients with high risk myelodysplastic syndromes or secondary acute myeloid leukaemia who have failed to respond adequately to hypomethylating agents.

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tosedostat (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 11 Jan 2016 Planned initiation date changed from 1 Dec 2012 to 1 Jan 2016, as per CTI BioPharma media release.
    • 01 Aug 2012 Planned initiation date changed from 1 Jun 2012 to 1 Dec 2012.
    • 13 Dec 2011 Planned initiation date changed from 1 Oct 2011 to 1 Jun 2012, according to a Chroma Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top